New data from the National Comprehensive Cancer Network (NCCN) reveal that socially vulnerable and minority patients with ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.

Gastric cancer (GC) is a leading cause of cancer-related deaths worldwide, with more than one million new diagnoses annually.

The FDA has granted approval to nivolumab plus ipilimumab for use in unresectable or metastatic hepatocellular carcinoma.

Approval of Opdivo plus Yervoy combination was based on results from the Phase III CheckMate-9DW trial, which demonstrated ...

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) as first-line treatment for adults with unresectable or metastatic HCC.

The combination therapy can be used as first-line treatment for unresectable or metastatic forms of the cancer.

The FDA has approved Opdivo with Yervoy for the first-line treatment of adults with unresectable or metastatic hepatocellular ...

The Food and Drug Administration (FDA) has approved Opdivo ® (nivolumab) in combination with Yervoy ® (ipilimumab) for the first-line treatment of adult patients with unresectable or metastatic ...